Elena Ridloff - 20 Jun 2025 Form 4 Insider Report for Kronos Bio, Inc. (KRON)

Reporting relationship: Director
Issuer ticker: KRON
Reported as of: 20 Jun 2025
Net transaction value: -$14,419
SEC form: 4
Accepted by SEC: 20 Jun 2025, 16:15:35 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Elena Ridloff

Key filing fact

Elena Ridloff filed Form 4 for Kronos Bio, Inc. (KRON) on 20 Jun 2025.

Key facts

This page summarizes Elena Ridloff's Form 4 filing for Kronos Bio, Inc. (KRON).
7 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 20 Jun 2025, 16:15.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: -$14,419.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001772518 Primary reporting owner

Ridloff Elena

Relationship: Director
Address: C/O KRONOS BIO, INC., 301 BINNEY STREET, 2ND FLOOR EAST, CAMBRIDGE
Signature: /s/ Elena Ridloff
Signature date: 20 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KRON transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $14,419
Shares: -25,296
Change %: -100%
Price: $0.5700
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -25,879
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,879
Exercise price: $13.35
Footnotes: F3

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -26,871
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,871
Exercise price: $13.35
Footnotes: F3

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -15,450
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,450
Exercise price: $24.18
Footnotes: F3

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -34,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,000
Exercise price: $3.53
Footnotes: F3

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -17,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $1.48
Footnotes: F3

KRON transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -17,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $0.9500
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Elena Ridloff is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

Footnote F2

[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

Footnote F3

As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.